Cantor Fitzgerald started coverage on shares of Tvardi Therapeutics (NASDAQ:TVRD - Free Report) in a report published on Friday, Marketbeat reports. The firm issued an overweight rating and a $52.00 price objective on the stock.
A number of other research firms also recently weighed in on TVRD. Oppenheimer began coverage on shares of Tvardi Therapeutics in a research note on Wednesday, May 21st. They issued an "outperform" rating and a $65.00 price target on the stock. Piper Sandler began coverage on shares of Tvardi Therapeutics in a report on Thursday, June 12th. They issued an "overweight" rating and a $78.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Tvardi Therapeutics to a "hold" rating in a report on Saturday, May 24th.
Read Our Latest Report on Tvardi Therapeutics
Tvardi Therapeutics Stock Performance
Shares of TVRD stock traded up $4.67 on Friday, hitting $27.34. The company's stock had a trading volume of 96,236 shares, compared to its average volume of 86,081. Tvardi Therapeutics has a fifty-two week low of $8.13 and a fifty-two week high of $34.31.
Tvardi Therapeutics Company Profile
(
Get Free Report)
Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
Read More
Before you consider Tvardi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tvardi Therapeutics wasn't on the list.
While Tvardi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
